Arcus Biosciences Inc
NYSE:RCUS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.69
20.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Arcus Biosciences Inc
Arcus Biosciences Inc
Revenue
Arcus Biosciences Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arcus Biosciences Inc
NYSE:RCUS
|
Revenue
$263m
|
CAGR 3-Years
91%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Arcus Biosciences Inc
Revenue Breakdown
Breakdown by Geography
Arcus Biosciences Inc
Breakdown by Segments
Arcus Biosciences Inc
|
Total Revenue:
117m
USD
|
|
License And Development Services Revenue:
80m
USD
|
|
License And R&D Services:
79m
USD
|
|
Other Collaboration Revenue:
37m
USD
|
|
Access Rights:
33m
USD
|
|
R&D Services:
5m
USD
|
Arcus Biosciences Inc
Glance View
Arcus Biosciences Inc., founded in 2015 and based in California, emerges not just as a company, but as a dynamic player in the biopharmaceutical arena with a fervent focus on innovative cancer therapies. The company's narrative is centered around harnessing the power of immunotherapy to combat cancer, a testament to its commitment to push the frontiers of medicine. At the core of Arcus's strategy is its proprietary pipeline of novel molecules designed to promote antitumor immune responses, particularly small-molecule drugs and antibodies. By marrying cutting-edge science with practical clinical applications, Arcus aims to provide treatments that enhance the body's immune response against cancer, offering hope to patients and healthcare providers alike. As Arcus Biosciences spins its operational wheel, its financial engine is fueled primarily through strategic partnerships and licensing agreements. The company collaborates with major pharmaceutical players to co-develop and commercialize its promising candidates, allowing it to share the risks and rewards inherent in drug development. These partnerships not only provide upfront payments and milestone-based financial inflows but also broaden the scope of clinical trials and expedite the pathway to market availability. By aligning their interests with larger entities invested in cutting-edge oncology solutions, Arcus is positioned to capitalize on the symbiotic relationship between innovative early-stage science and the expansive reach of established pharmaceutical channels, striving to bring transformative therapies to the global market.
See Also
What is Arcus Biosciences Inc's Revenue?
Revenue
263m
USD
Based on the financial report for Sep 30, 2024, Arcus Biosciences Inc's Revenue amounts to 263m USD.
What is Arcus Biosciences Inc's Revenue growth rate?
Revenue CAGR 5Y
107%
Over the last year, the Revenue growth was 120%. The average annual Revenue growth rates for Arcus Biosciences Inc have been 91% over the past three years , 107% over the past five years .
You don't have any saved screeners yet
